Aclarion Inc. (NASDAQ: ACON, ACONW) appointed Daniel Keefe as Commercial Director for the Western United States to support expansion of its Nociscan platform for chronic low back pain diagnosis.

Keefe brings more than 20 years of medical device and healthcare technology sales experience, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. He most recently served as Regional Sales Manager at Centinel Spine, where the company said he exceeded performance targets and delivered growth across Northern California.

The appointment reflects what Aclarion describes as increasing demand for Nociscan, which the company reports has experienced triple-digit growth in utilization. The platform uses magnetic resonance spectroscopy data and biomarkers to help physicians identify painful discs in the lumbar spine.

"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies," said Brent Ness, Chief Executive Officer of Aclarion. "His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S."

Aclarion's Nociscan solution is designed to noninvasively distinguish between painful and nonpainful discs in the lumbar spine using cloud-based analysis of MRS data. The company states the platform demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.

The Colorado-based healthcare technology company has established presence across the Western United States, with engagement spanning academic institutions and private practice spine centers. The company estimates 266 million people worldwide live with chronic low back pain.